SQLite Web: event_store.db

Update row 27945 in events

seq

Primary key. INTEGER

id

TEXT NOT NULL

kind

TEXT NOT NULL

ts

TEXT NOT NULL

actor

TEXT

subject_entity_ids

TEXT

payload

{"created_at":"2026-04-12T06:42:42.365745+00:00","dedupe_key":"signal_enriched:discovery_unusual_volume_delta:61a2f832ea05a367","evidence_event_ids":["evt_2c5892ebf47c"],"signal_type":"discovery_unusual_volume_delta","source":"discovery_ingestor","value":{"aggregator_url":"https://www.nasdaq.com/articles/better-buy-right-now-johnson-johnson-vs-pfizer","as_of":"2026-04-12T06:42:42.365745+00:00","canonical_url":"https://www.fool.com/investing/2026/04/12/better-buy-right-now-johnson-johnson-vs-pfizer/","enrichment":{"aggregator_url":"https://www.nasdaq.com/articles/better-buy-right-now-johnson-johnson-vs-pfizer","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_0b8a63eed2f9a982","canonical_host":"fool.com","canonical_is_aggregator":false,"canonical_url":"https://www.fool.com/investing/2026/04/12/better-buy-right-now-johnson-johnson-vs-pfizer/","content_type":"text/html; charset=utf-8","enriched_at":"2026-04-12T06:43:36.657207+00:00","extraction_method":"trafilatura","fetched_description":"Key PointsJohnson & Johnson is one of the largest pharmaceutical stocks by market cap.","fetched_title":"Better Buy Right Now: Johnson & Johnson Vs. Pfizer | Nasdaq","final_url":"https://www.nasdaq.com/articles/better-buy-right-now-johnson-johnson-vs-pfizer","html_truncated":false,"paywall_likely":false,"publisher_domain":"fool.com","publisher_resolution":"canonical_url","requested_url":"https://www.nasdaq.com/articles/better-buy-right-now-johnson-johnson-vs-pfizer","source_event_id":"evt_2c5892ebf47c","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"fp":"09bf4a74ba25c92a","kind":"unusual_volume","published_at":"2026-04-12T05:20:00+00:00","publisher_domain":"fool.com","signal_understanding":{"analysis_basis":"article","claim_confidence":0.72,"dates_mentioned":["2022","2023","2024","2025","November 2025","2026"],"entities":[{"asset_class":"equity","name":"Johnson & Johnson","relevance":"high","symbol":"JNJ","type":"company"},{"asset_class":"equity","name":"Pfizer","relevance":"high","symbol":"PFE","type":"company"},{"asset_class":"equity","name":"Kenvue","relevance":"medium","symbol":"","type":"company"},{"asset_class":"equity","name":"Seagen","relevance":"medium","symbol":"","type":"company"},{"asset_class":"equity","name":"Metsera","relevance":"medium","symbol":"","type":"company"}],"event_type":"other","information_gaps":["Unusual volume details are missing: no ticker-specific volume ratio vs average, no baseline volume, and no direction (e.g., above/below average) are provided in the provided text.","The signal\u2019s catalyst hypothesis is not explicitly stated; the article is a comparative valuation/growth/dividend discussion rather than a trading-volume explanation.","No confirmation mechanism is described (e.g., whether the volume spike is tied to a specific news event).","The headline suggests a comparison, but the text does not mention any trading-volume anomaly or market event tied to it."],"key_facts":["The article states J&J is one of the largest pharmaceutical stocks by market cap.","The article states Pfizer\u2019s dividend yield is over 6% and J&J\u2019s dividend yield is 2.1%.","The article states J&J recorded $88.8 billion in revenue in 2024 and expects 2026 sales of $99.5B to $100.5B.","The article states Pfizer revenue fell from around $100B in 2022 to $59.5B in 2023.","The article states Pfizer acquired Seagen to strengthen its oncology segment.","The article states Pfizer acquired Metsera in November 2025 to strengthen its anti-obesity market.","The article states J&J increased its dividend payout for more than 60 consecutive years.","The article states Pfizer\u2019s forward P/E is 9.6 and J&J\u2019s forward P/E is 21.1.","The article concludes it would give the edge to J&J in the comparison."],"numeric_claims":[{"label":"JNJ revenue (2024)","value":"$88.8 billion"},{"label":"JNJ expected sales (2026)","value":"$99.5B to $100.5B"},{"label":"PFE revenue (2022 approx.)","value":"~$100 billion"},{"label":"PFE revenue (2023)","value":"$59.5 billion"},{"label":"PFE forecast revenue (2026)","value":"$59.5B to $62.5B"},{"label":"PFE dividend yield","value":"> 6%"},{"label":"JNJ dividend yield","value":"2.1%"},{"label":"PFE forward P/E","value":"9.6"},{"label":"JNJ forward P/E","value":"21.1"},{"label":"Oncology market growth (Fortune Business Insights)","value":"~$286B in 2026 to >$679B by 2034"}],"primary_claim":"The article\u2019s investment comparison concludes that Johnson & Johnson has the edge over Pfizer based on revenue growth and more reliable dividend sustainability.","relevance_score":0.35,"sentiment":"mixed","source_quality":"high","summary":"The article compares Johnson & Johnson (JNJ) and Pfizer (PFE), arguing J&J has stronger growth and dividend sustainability while Pfizer relies more on acquisitions and faces revenue/pipeline uncertainty. No specific unusual trading volume or volume-vs-average ratio is provided in the text.","topics":["healthcare","pharmaceuticals","dividends","revenue growth","acquisitions","pipeline","valuation","stock comparison"]},"source":"Nasdaq Markets","source_domain":"fool.com","summary":"Key PointsJohnson & Johnson is one of the largest pharmaceutical stocks by market cap.","tickers":[],"title":"Better Buy Right Now: Johnson & Johnson Vs. Pfizer","url":"https://www.fool.com/investing/2026/04/12/better-buy-right-now-johnson-johnson-vs-pfizer/"}}

TEXT NOT NULL

source_ref

TEXT

confidence

REAL (default 0.0

dedupe_key

TEXT

episode_id

TEXT

created_at

TEXT NOT NULL (default strftime('%Y-%m-%dT%H:%M:%fZ','now')

Cancel